Serum salusin-β levels in patients with systemic lupus erythematosus

[1]  L. Rudnicka,et al.  The Clinical Significance of Salusins in Systemic Sclerosis—A Cross-Sectional Study , 2023, Diagnostics.

[2]  M. Akyıldız,et al.  Serum salusin-α and salusin-β levels in patients with psoriatic arthritis , 2022, Reumatologia.

[3]  N. Shen,et al.  Expanding Roles of Noncoding RNAs in the Pathogenesis of Systemic Lupus Erythematosus , 2022, Current Rheumatology Reports.

[4]  Y. Nagafuchi,et al.  Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus , 2021, Biomolecules.

[5]  Hongmei Chen,et al.  Downregulation of Salusin-β protects renal tubular epithelial cells against high glucose-induced inflammation, oxidative stress, apoptosis and lipid accumulation via suppressing miR-155-5p , 2021, Bioengineered.

[6]  L. Arnaud,et al.  Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors , 2020, Rheumatology.

[7]  Xiaolu Mao,et al.  Salusin-β is superior to salusin-α as a marker for evaluating coronary atherosclerosis , 2020, The Journal of international medical research.

[8]  Hai-Jian Sun,et al.  Salusin-β mediates tubular cell apoptosis in acute kidney injury: Involvement of the PKC/ROS signaling pathway , 2019, Redox biology.

[9]  D. Pisetsky.  Evolving story of autoantibodies in systemic lupus erythematosus. , 2019, Journal of autoimmunity.

[10]  D. Gladman,et al.  2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus , 2019, Arthritis & rheumatology.

[11]  A. Tincani,et al.  Endothelial Dysfunction in Early Systemic Lupus Erythematosus Patients and Controls Without Previous Cardiovascular Events , 2018, Arthritis care & research.

[12]  L. Ling,et al.  Endothelial dysfunction in systemic lupus erythematosus – a case-control study and an updated meta-analysis and meta-regression , 2017, Scientific Reports.

[13]  P. D. de Groot,et al.  Mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome. , 2017, Best practice & research. Clinical rheumatology.

[14]  Hai-Jian Sun,et al.  Salusin-β contributes to vascular remodeling associated with hypertension via promoting vascular smooth muscle cell proliferation and vascular fibrosis. , 2015, Biochimica et biophysica acta.

[15]  S. Aydin,et al.  Serum salusin-α and salusin-β levels in patients with Behcet’s disease , 2014, European Journal of Dermatology.

[16]  A. Işık,et al.  Serum salusin-α levels in systemic lupus erythematosus and systemic sclerosis. , 2014, European journal of rheumatology.

[17]  M. Shichiri,et al.  Salusins: Potential Use as a Biomarker for Atherosclerotic Cardiovascular Diseases , 2013, International journal of hypertension.

[18]  M. Shichiri,et al.  Circulating Levels of Human salusin-β,a Potent Hemodynamic and Atherogenesis Regulator , 2013, PloS one.

[19]  M. Shichiri,et al.  Salusin-β accelerates inflammatory responses in vascular endothelial cells via NF-κB signaling in LDL receptor-deficient mice in vivo and HUVECs in vitro. , 2012, American journal of physiology. Heart and circulatory physiology.

[20]  A. Işık,et al.  Serum salusin-alpha level in rheumatoid arthritis , 2011, Regulatory Peptides.

[21]  M. Shichiri,et al.  Release of salusin-β from human monocytes/macrophages , 2010, Regulatory Peptides.

[22]  M. Shichiri,et al.  Presence of immunoreactive salusin-β in human plasma and urine , 2009, Regulatory Peptides.

[23]  T. Ota,et al.  Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities , 2003, Nature Medicine.

[24]  M. Brin,et al.  The TOR1A (DYT1) gene family and its role in early onset torsion dystonia. , 1999, Genomics.